Citius rises on expanding trial sites outside U.S.

Citius Pharmaceuticals

06/05/2022 17:32

** Shares of drug developer  CTXR.O  rise 9.4% to $1.06
    ** Co says it is expanding late-stage trial of Mino-Lok to
sites outside U.S. (https://refini.tv/3w8U5hg)
    ** Mino-Lok is co's experimental antibiotic therapy to
salvage infected central venous catheters causing
catheter-related blood stream infections
    ** CTXR paused ex-U.S. strategy as COVID-19 spread across
the globe and hospitals halted non-COVID trials; with pandemic
receding, there is now opportunity to access additional sites -
CEO
    ** Co has selected clinical research organization selected
Biorasi LLC to help expand trial internationally
    ** Additional sites to support trial completion by end of
2022

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))